NLS Biotech News

Biotech Business – April 16, 2026

EIB backs BioLamina with EUR 20 million

The European Investment Bank (EIB) is lending EUR 20 million to BioLamina to expand its development of laminin technologies.

Biotech Business – April 14, 2026

Alzinova initiates collaboration with Amsterdam UMC

The research collaboration aims to develop a blood‑based test that measures naturally occurring antibodies against toxic amyloid‑β oligomers in healthy individuals, based on Alzinova’s Aβ42CC oligomer technology.

Pharma Inspiration Day | Microsoft Office, Copenhagen | EVENT

The global pharma community is moving at an incredible pace, and the Pharma Inspiration Day on May 5th in Copenhagen is your chance to be in the room with the people setting that tempo.

Biotech Business – April 7, 2026

Biosergen Pauses Development of BSG005

Against the backdrop of a continued challenging financing environment, the Board of Directors of Biosergen has resolved to pause the development of BSG005.

Biotech Business – March 27, 2026

Sprint Bioscience publishes new research findings

Sprint Bioscience is taking further steps in its DCPS program through a new study that reinforces the scientific support for DCPS inhibition as a promising treatment strategy for acute myeloid leukemia (AML).

Clinical trials

Clinical Trials – April 15, 2026

Promising results about new Lyme disease vaccine candidate

Pfizer and Valneva’s Lyme disease vaccine candidate demonstrated strong efficacy in their Phase 3 VALOR trial.

Clinical Trials – April 13, 2026

Mendus starts clinical program in chronic myeloid leukemia

The company has completed preparations and received all regulatory approvals for the VITAL-CML trial.

Clinical Trials – April 13, 2026

Diamyd Medical discontinues Phase 3 trial and initiates strategic review

Diamyd Medical has announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes.

Clinical Trials – April 1, 2026

Cereno Scientific reports 12-month data

The company has announced initial learnings from the 12-month Expanded Access Program (EAP) with its lead drug candidate CS1 in pulmonary arterial hypertension (PAH).

Clinical Trials – March 31, 2026

Affibody reports positive Phase 3 data

The company has announced positive 32-week data from a global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa (HS).

Clinical Trials – March 25, 2026

Verigraft initiates Phase II/III trial of its personalized tissue engineered vein

The company has announced the initiation of a pivotal Phase II/III trial of its P-TEV (personalized tissue engineered vein) in patients with chronic venous insufficiency (CVI), supported by USD 10 million from existing investors.

Clinical Trials – March 23, 2026

BioArctic presents new data on long-term, real-world treatment with lecanemab

BioArctic’s partner Eisai presented the data at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, held in Copenhagen, Denmark March 17-21.

Clinical Trials – March 20, 2026

Lundbeck advances Parkinson’s research with new Phase 1b data

The company has presented new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel compound invented by Lundbeck with dopamine D1/D2 receptor agonist activity.

Clinical Trials – March 15, 2026

Oslo University Hospital begins study with TikoMed’s drug candidate

Oslo University Hospital has begun the inclusion of patients in the IMPACT study, which aims to investigate the efficacy and safety of TikoMed’s candidate drug ILB compared to riluzole for the treatment of ALS.

Clinical Trials – March 9, 2026

Oncopeptides secures fast-track designation for Window-of-Opportunity study

Oncopeptides has achieved key regulatory agreement with both the Swedish and Norwegian Medical Products Agencies regarding the design of its planned “Window-of-Opportunity” study evaluating a Peptide Drug Conjugate (PDC) in glioblastoma.

Profiles in Biotech

Profiles in Biotech – April 23, 2024

Mia Phillipson: Pioneering immunotherapies

Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur.

Profiles in Biotech – November 28, 2023

Kristian Tryggvason: Reshaping the cell therapy sector

The previous founder and CEO of BioLamina has gone back to business development, and with his newly founded company he aims to redefine cell therapy development even further.

Profiles in Biotech – July 28, 2021

Mathias Uhlén: Driven by curiosity and courage

Being a scientist or an entrepreneur is hard enough. Doing both at the same time sounds like an Olympic sport.

Profiles in Biotech – March 8, 2021

Sara Mangsbo – Scientist and entrepreneur

An academic and an entrepreneur, Dr. Sara Mangsbo, PhD, has found a way to integrate her skills and interests so that they complement and augment her passions.

Profiles in Biotech – January 7, 2021

Evelina Vågesjö: ”I want to see my work go beyond the lab”

What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company.

Profiles in Biotech – October 8, 2020

Robert Langer: Making a difference in medicine

Massachusetts Institute of Technology (MIT) in the US has produced more than its share of engineers and computer scientists, but unlike many of his peers, alumnus Dr. Robert Langer, ScD, turned his chemical engineering skills to medicine, becoming one of the world’s leaders in perfecting effective drug delivery systems.

Profiles in Biotech – June 13, 2018

Britt Meelby Jensen: Accelerating Danish biotech business

She has been called the Danish biotech queen and she is not afraid of responsibility in her role as CEO. On the contrary, Britt Meelby Jensen enjoys leading, setting ambitious goals and accelerating company growth.

Profiles in Biotech – October 6, 2017

Next-generation biotech entrepreneurs

For young scientists and engineers, a startup can be part of early training and education.

Profiles in Biotech – December 16, 2016

Agnete Fredriksen: “You really need to have drive to make it work”

Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula.

More biotech stories

Biotech Business - April 13, 2026

Alligator Bioscience gives update on mitazalimab

In parallel with ongoing partnering activities, Alligator is exploring alternative opportunities for phase 3 development of mitazalimab in first line metastatic pancreatic cancer.

Biotech Business - March 25, 2026

Tenboron receives EUR 7.6 million EU funding

Tenboron has received a positive funding decision from the European Union Horizon Europe Health 2025 programme for Phase 1 and 2 clinical studies of its TB0010 boron carrier for Boron Neutron Capture Therapy (BNCT).

Agreement - March 25, 2026

Genovis in non-exclusive license agreement with US biotech company

Genovis has entered into a non-exclusive, worldwide license agreement with a US-based private biotech company, granting rights to use Genovis’ EndoS2 enzyme technology for the research, development, manufacture, and commercialization of antibody-drug conjugate (ADC) therapeutics.

Biotech Business - March 19, 2026

FluoGuide receives FDA Fast Track Designation

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to FG001 as an intraoperative imaging agent to guide surgical resection of high-grade glioma.

Biotech article - March 3, 2026

The power of powder: Nasal drug delivery for quicker uptake

Nasal drug delivery is a dynamic area in pharmaceutical innovation. What was once a route for decongestants and allergy sprays is now being explored for everything from emergency treatments to vaccines – and even shows potential for future central nervous system therapies.